Try our beta test site

Local Measures to Prevent Diabetes in the Værnes Region. (VEND-RISK)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT01135901
First received: April 26, 2010
Last updated: January 20, 2017
Last verified: January 2017
  Purpose
This is a development project involving four different municipalities in Central Norway. The aim is to identify adults with overweight and with an increased risk of developing diabetes mellitus type 2, then to prevent the disease to develop by the means of a behaviour change programme. The programme is group based.

Condition Intervention
Diabetes Mellitus Type 2
Obesity
Behavioral: Behavioural change programme

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: The VEND RISK-study. Preventing Diabetes Type 2 in Overweight Persons in the Værnes Region, Central-Norway.

Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Diabetes mellitus type 2 [ Time Frame: Visit 1 (baseline) till Visit 9 (5 years) ]

Enrollment: 180
Study Start Date: April 2010
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: group programme
Group based behaviour change programme
Behavioral: Behavioural change programme
The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Living in Central Norway
  • Find Risc score > 15
  • Written, informed consent

Exclusion Criteria:

  • Severe mental disorder
  • Not being able to function in the group programme
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01135901

Locations
Norway
Vaernesregionen
Meraker, Stjordal, Selbu, Tydal, Norway
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Bård Kulseng, PhD Norwegian University of Technology and Science
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT01135901     History of Changes
Other Study ID Numbers: 2010/696-2 
Study First Received: April 26, 2010
Last Updated: January 20, 2017

Keywords provided by Norwegian University of Science and Technology:
prevention
public health
community health services
Norway

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on February 23, 2017